Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance
Authors:
- Takashi YamamuraTYTakashi Yamamura
- Noriko IsobeNINoriko Isobe
- Izumi KawachiIKIzumi Kawachi
- Yusei MiyazakiYMYusei Miyazaki
- Minami TomitaMTMinami Tomita
- Takahiko TsumurayaTTTakahiko Tsumuraya
- Katsuhisa YamashitaKYKatsuhisa Yamashita
- Jin NakaharaJNJin Nakahara
- Ichiro NakashimaINIchiro Nakashima
- Kazuo FujiharaKFKazuo Fujihara
Open Access
- 16 July 2024
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 13 (5) , 1361-1383
Abstract
Introduction Satralizumab, an anti-interleukin-6 receptor antibody, is approved in Japan for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD) and is undergoing post-marketing surveillance (PMS) of clinical use. We aimed to describe the real-world safety and effectiveness of satralizumab in Japanese patients with NMOSD. Methods This is an ongoing PMS (planned completion: February 2027). This 6-month interim analysis assessed the safety and effectiveness of satralizumab in Japanese patients with NMOSD using data collected from August 2020 to July 2021. Results Among 570 patients who participated, 523 (91.75%) were female and the mean ± standard deviation (SD) age was 52.4 ± 14.1 years. At baseline, NMOSD expanded disability status scale mean ± SD was 4.19 ± 2.19; 490 (85.96%) patients used glucocorticoids and 277 (48.59%) patients used immunosuppressants concomitantly. Of 570 satralizumab-treated patients, 85 (14.91%) had discontinued satralizumab treatment at 6 months. For the overall adverse drug reactions (ADRs), 76.22 (66.07–87.48) events/100 person-years occurred in 118 (20.70%) patients, and infections occurred in 28 (4.91%) patients. Serious infections occurred in 18 (3.15%) patients, with an event rate of 9.05 (5.80–13.47) events/100 person-years. Of the 24 events of serious infections, respiratory tract infections (29.17%; 7) and urinary tract infections (25.00%; 6) were the most common serious infection events. One fatal ADR (septic shock) suspected to be related to satralizumab was reported. The mean ± SD glucocorticoid dose reduced from 12.28 ± 10.17 mg/day at the index date to 8.11 ± 7.30 mg/day at 6 months. The Kaplan–Meier cumulative relapse-free rate (95% confidence interval) was 94.59% (92.25–96.23) at 6 months. Conclusion In this study, satralizumab was found to be safe, well tolerated, and effective in patients with NMOSD in routine clinical practice. The results are consistent with those of previous clinical trials. The safety and effectiveness of satralizumab in Japanese patients with NMOSD will be analyzed over the 6-year surveillance period. Trial Registration: UMIN Clinical Trials Registry, UMIN000041047.Keywords
Funding Information
- Chugai Pharmaceutical Co, Ltd.
This publication has 21 references indexed in Scilit:
- Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims databaseMultiple Sclerosis and Related Disorders, 2024
- Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescentsArquivos de Neuro-Psiquiatria, 2023
- Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStarMultiple Sclerosis and Related Disorders, 2022
- Update on neuromyelitis optica spectrum disorderCurrent Opinion in Ophthalmology, 2020
- Satralizumab: First ApprovalDrugs, 2020
- Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trialThe Lancet Neurology, 2020
- Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment optionsExpert Review of Neurotherapeutics, 2020
- Trial of Satralizumab in Neuromyelitis Optica Spectrum DisorderNew England Journal of Medicine, 2019
- Long-term Systemic Corticosteroid Exposure: A Systematic Literature ReviewClinical Therapeutics, 2017
- Risk of Infectious Complications in Patients Taking GlucocorticosteroidsClinical Infectious Diseases, 1989